A Study of IOV-5001 in Adults With Advanced Solid Tumors

Sponsor
Iovance Biotherapeutics, Inc.
Study ID
NCT07743723
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • IOV-5001 — BIOLOGICAL
    IOV-5001 will be administered as 2 infusions, which will be administered in a hospital setting.

Study Details

A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors

Key Dates

First listed
Aug 4, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2034
Completion
Mar 31, 2044

Study Design

Enrollment
106 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1: Safety Lead In
  • Experimental: Phase 2: Non-Small Cell Lung Cancer (NSCLC)
  • Experimental: Phase 2: Triple Negative Breast Cancer (TNBC)
  • Experimental: Phase 2: Colorectal Cancer (CRC)
  • Experimental: Phase 2: Head and Neck Squamous Cell Carcinoma (HNSCC)

Primary Outcome Measure

Phase 1: Safety Assessment [ Time Frame: Up to 30 days ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsHead and neck cancer trialsLung cancer trialsOncology trialsGI oncology trialsENT trialsLung oncology trialsLung disease trials

Related Studies